Abstract:

Objective:To discuss the of histone deacetylase 7(HDAC7) in bone marrow samples of patients with newly diagnosed pediatric acute lymphoblastic leukemia (ALL) and the association with clinic-biological characteristics, early treatment responses and long-term outcome.Methods: The HDAC7 level of pediatric patients with newly diagnosed ALL was determined by RT-qPCR method. Three samples from ALL patients in CCR for more than 3 years after treatment were used as control and patients were divided into high-（≥1.0） and low- （<1.0）groups．The differences of clinico-biological characteristics, minimal residual disease and event-free survival (EFS) were analyzed between high and low groups. Results: HDAC7 of 236 pediatric patients with newly diagnosed ALL ranged from 0.046 to 10.581, with 124 and 112 patients in the high group and low group, respectively. Univariate analysis showed that the of HDAC7 was associated with low peripheral white blood count （WBC） at diagnosis（＜50×109·L-1 ）, pro-B immunophenotype and MLL gene rearrangement（all P＜0.05）. Logistic multivariate regression analysis showed that WBC （＜50×109·L-1 ）and fusion gene were influence factors of HDAC7 （all P＜0.05）. Intermediate risk group patients with high- of HDAC7 was associated with a favorable 5 year EFS compared with low- group, with（91.0±3.5）% vs. （75.5±4.9）%，P=0.013. Furthermore, HDAC7 was indentified as the independent prognostic factor for EFS in IR patients, with odd ratio and 95% confidence interval of 1.26（1.31~9.51）. Conclusion: In pediatric ALL, of HDAC7 was found to be related to clinical and biological characteristics. Low-HDAC7 was independent adverse prognostic factor for EFS in IR subgroup.